The effects of rituximab on serum IgE and BAFF

Short report

Angira Dasgupta, Katherine Radford, Donald M Arnold, Lehana Thabane and Parameswaran Nair

Author Affiliations

For all author emails, please log on.

Allergy, Asthma & Clinical Immunology 2013, 9:39 doi:10.1186/1710-1492-9-39

Published: 3 October 2013

Abstract (provisional)

Background

There are few treatment options for patients with severe atopic asthma. Antagonism of IgE is an effective strategy. We investigated, by utilizing serum samples from a clinical trial of Rituximab in patients with Idiopathic Thrombocytopenic Purpura, if B cell depletion would decrease serum IgE and therefore be a potential therapeutic option.

Findings: In a placebo-controlled randomized clinical trial of Rituximab, an anti-CD20 molecule, there were no significant differences in serum levels of IgE or BAFF levels between the two treatment groups at 3 or 6 months irrespective of the baseline serum IgE levels.

Conclusions

Since Rituximab did not significantly decrease serum IgE levels, this proof of concept study suggests that Rituximab may not be a useful treatment strategy for patients with severe IgE mediated disease.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.